In accordance, the inhibition of enhanced autophagy by TTCC blockers reduce tumor aggressiveness in recurrent Vemurafenib-resistant melanomas, decrease Cav3.1 expression, and avoid the acquisition of resistance to BRAFi treatment in BRAFV600E-mutant melanoma cells [22,93]. This evidence concerns the gene CACNA1G and neoplasm.